Targeted Oncology Staff | Authors

Articles

Salani Reviews Role of PARP Inhibition in Ovarian Cancer

November 24, 2022

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.

Efebera Discusses Different Regimens for Transplant-Eligible NDMM

November 23, 2022

During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.

Roundtable Discussion: Barata and Participants Explore Later-Line Options in Bladder Cancer

November 22, 2022

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed with participants their approaches to therapy for a patient whose bladder cancer progresses after receiving chemotherapy and immunotherapy.

Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC

November 21, 2022

During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.